Updated:
Portage Biotech Inc.
Portage Biotech Inc. (NASDAQ: PRTG) is a clinical-stage immuno-oncology company advancing first-in-class therapies targeting checkpoint resistance...
Portage Biotech Inc.
Portage Biotech Inc. (NASDAQ: PRTG) is a clinical-stage immuno-oncology company headquartered in Tortola, British Virgin Islands, with a secondary office in Dover, Delaware. The firm is led by CEO Dr. Ian B. Walters and CFO Dr. Matthew M. Heck, and describes itself as a unique entity that catalyzes R&D to produce quality clinical programs. The firm's strategy centres on advancing first-in-class therapies that target known checkpoint resistance pathways. Portage actively engages in drug development from bench through human proof of concept, using a fail-fast approach to review hundreds of asset combinations. Nine products are currently in preclinical or clinical development across five drug platforms, with a focus on oncology (per the firm, 2026). Portage maintains a clinical-stage pipeline of immuno-oncology assets, and its team has collectively contributed to five oncology drug approvals and created high-value exits (per the firm). Recent activity: unknown — no verifiable events within the last 24 months were found. A structural differentiator for Portage is its model of providing strategic counsel and active engagement in the drug development process, aiming to reduce risks through efficient capital management and scientific oversight. This hybrid of a drug development organization and a capital allocator is distinct from a traditional biotech or family office.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Latin America
Country
British Virgin Islands
City
Tortola
Corporate office
Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110, British Virgin Islands
Additional offices
1111B S Governors Ave STE 25907, Dover, DE 19904, USA
Principals
Dr. Ian B. Walters
Chief Executive Officer
Dr. Matthew M. Heck
Chief Financial Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Portage Biotech?
Decisions are led by CEO Dr. Ian B. Walters and CFO Dr. Matthew M. Heck, supported by a team of scientists, clinicians, and pharma-experienced executives (per firm website).
How does Portage Biotech source proprietary deal flow?
Portage reviews hundreds of assets and asset combinations through its fail-fast approach, selecting only the most promising to advance (per firm). The firm leverages a strong industry network for sourcing.
Is Portage Biotech structured as a single family office or a venture firm?
Portage Biotech is a clinical-stage immuno-oncology company, not a family office. It is a publicly traded entity on NASDAQ and operates as a drug development organization.
What investment stages does Portage Biotech typically target?
Portage targets preclinical and clinical-stage oncology assets, advancing them through to proof of concept. It focuses on first-in-class therapies targeting checkpoint resistance pathways.
Which sectors does Portage Biotech explicitly focus on?
Portage focuses exclusively on oncology/immuno-oncology, specifically first-in-class therapies that target known checkpoint resistance pathways (per firm).
Where does the underlying wealth come from for Portage Biotech?
The firm is publicly traded on NASDAQ under ticker PRTG, and its capital comes from equity markets, not a disclosed private wealth source.
What is Portage Biotech's known posture on co-investments alongside external GPs?
Portage Biotech does not publicly discuss co-investment with external GPs. Its operations are internal drug development, not fund investment.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: